Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,666 matching trials from the live ClinicalTrials.gov search.
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of 18 F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass

NCT02236754
Conditions
Healthy Volunteers, Diabetes Mellitus, Type 1
Interventions
18 F-FP-DTBZ, PET Scanning
Drug · Radiation
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Conditions
Type 1 Diabetes
Interventions
CT-868, Placebo, Victoza
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Type 1 Diabetes
Interventions
Dexcom G7 rtCGM, Capillary Blood glucose Testing (POC)
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Active, not recruiting Not applicable Interventional

Device Use Reimagined Through Education And Mentorship

NCT06546930
Conditions
Diabetes Mellitus, Type 1
Interventions
DREAM intervention
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Davis, California • Los Angeles, California • San Francisco, California
Active, not recruiting Not applicable Interventional

FAMS-T1D Self-Regulation and Social Support for T1D

NCT05820477
Conditions
Type 1 Diabetes
Interventions
FAMS-T1D, Digital resources for diabetes
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 24 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Salt Lake City, Utah
Completed Phase 2 Interventional Accepts healthy volunteers Results available

GPR119 Agonist for Hypoglycemia in Type 1 Diabetes

NCT04432090
Conditions
Diabetes Mellitus, Type 1
Interventions
Placebo, Study Medication (MBX-2982), No medication for this group
Drug · Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Completed Phase 4 Interventional Results available

Regadenoson Blood Flow in Type 1 Diabetes (RABIT1D)

NCT01019486
Conditions
Coronary Artery Disease, Type 1 Diabetes Mellitus
Interventions
Regadenoson myocardial perfusion imaging, Regadenoson MRI myocardial blood flow
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
25 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado
Active, not recruiting Not applicable Interventional

Diabetes Toolkit at Discharge

NCT05663931
Conditions
Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions
DM Discharge Toolkit
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Type 1 Diabetes Mellitus, Glycemic Control
Interventions
Bayer DCA2000+ Hemoglobin A1c analyzer
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2Phase 3 Interventional Results available

Insulin Delivery Using Microneedles in Type 1 Diabetes

NCT00837512
Conditions
Type 1 Diabetes Mellitus
Interventions
Microneedle, Subcutaneous insulin catheter
Device
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Advanced Solid Malignancies
Interventions
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
10
States / cities
Santa Rosa, California • Washington D.C., District of Columbia • Tinley Park, Illinois + 7 more
Conditions
Type 1 Diabetes
Interventions
Reinforcement for meeting targeted physical activity goals, Standard of Care
Behavioral · Other
Lead sponsor
Yale University
Other
Eligibility
13 Years to 24 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 1 Diabetes, Type 1 Diabetes (Juvenile Onset), Diabetes Mellitus, Type 1
Interventions
R-5280, Placebo
Drug · Other
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
11 Years to 17 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Plantation, Florida • Rochester, Minnesota • Dallas, Texas
Completed Not applicable Interventional Results available

CGM Use in Poorly Controlled Youth With Type 1 Diabetes

NCT04721145
Conditions
Type 1 Diabetes, Hypoglycemia, High Blood Sugar
Interventions
Dexcom G6 Continuous Glucose Monitor
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Type 1 Diabetes
Interventions
Glucagon Nasal Powder [Baqsimi]
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 4 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Jacksonville, Florida • Boise, Idaho • Indianapolis, Indiana + 5 more
Conditions
Melanoma
Interventions
MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin Degludec, Insulin Glargine
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 18 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Conditions
Type 1 Diabetes
Interventions
Estradiol, medroxyprogesterone, hydrocortisone, GH, Matching placebo
Drug
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Santa Barbara, California
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia
Conditions
Type1diabetes
Interventions
AHCL pump, Video conferencing Application
Device · Other
Lead sponsor
Children's Hospital New Orleans, LA
Other
Eligibility
10 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Orleans, Louisiana
Completed Not applicable Interventional Accepts healthy volunteers Results available

Advancing Understanding of Transportation Options

NCT04141891
Conditions
Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa, Vision Disorders, Acute Coronary Syndrome, Implantable Defibrillator User, Congestive Heart Failure, Hypertrophic Obstructive Cardiomyopathy, Orthostatic Hypotension, Syncope, Presyncope, Narcolepsy, Dementia, Multiple Sclerosis, Parkinson Disease, Brain Injuries, Spinal Cord Injuries, Stroke, Vertigo, Dizziness, Seizures, Substance Use, Insulin Dependent Diabetes Mellitus, Arthritis, Foot--Abnormalities, Chronic Obstructive Pulmonary Disease, Obstructive Sleep Apnea, End Stage Renal Disease, Sleep Apnea, Insomnia, Restless Legs Syndrome
Interventions
Driving Decision Aid, Older Drivers Website
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Indianapolis, Indiana
Conditions
Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
Interventions
Betaine (trimethyglycine)
Dietary Supplement
Lead sponsor
Southern California Institute for Research and Education
Other
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Long Beach, California